SMA CLINICAL TRIALS NEWS from FightSMA Annual Research Conference Sponsor Isis Pharmaceuticals: Isis has released results from their Phase 2 clinical studies of ISIS-SMN Rx. Dr. C. Frank Bennett, a frequent FightSMA ARC collaborator & Senior Vice President of Research at Isis, says of these findings: We continue to be encouraged with the dose- and time-dependent increases in both muscle function scores and SMN protein levels observed in children with SMA treated with ISIS-SMNRx…the consistency of the data supports our optimism that ISIS-SMNRx may be able to improve the lives of infants and children with SMA and gives us further confidence to advance ISIS-SMNRx into a Phase 3 program. We are on track to start the Phase 3 study in children with SMA later this year.
Posted on: Wed, 30 Apr 2014 16:39:19 +0000
Recently Viewed Topics
© 2015